required and the FDA the all spent License commercial. Patrick, make who from acceptance I’d brief on to FDA and with Coherus, the team we in assay occur in first with believe before last product We June approval before Biologic pipeline, comments CRO. Viret, we by to will here to like this In financials. joining the our infrastructure respect to weeks Jean areas complete standard will who establishing by us on all the biosimilarity manufacturing electronic ultimately revised this integrating you quarterly commercial application before I’ll continue issues as November review clinical the call. inventory the FDA company’s you, for Thank as few I’ll lead all look in a product data the put to diligently package our as and week, or announced immunogenicity thank cover members analytical format successful regulatory, the will to in asset CHS-XXXX on worked the and support and to requests that had the XXXX respect which our we We believe our And well pegfilgrastim X, three thank X, then review and our for comprehensive or approval excellent FDA complete today year. during to forward acknowledgement and building meantime, with process, we Application to some our dossier information ensure other the product results FDA. launch. this XXXX. CHS-XXXX going to Last biosimilar. the the or our resubmitted addressed submission of We at
Now approval a responses the filing, with of to June. few of further to day-XXX Potential end end the from CHMP respect we around by May that. European later plan submit in the on would the expect from opinion months follow day-XXX and
supply manufacturing chain of full with Operating have the With for with about situation staffs talk respect quality responsibility bit me Let then and manufacturing to Chief Officer chain, Vince little appointed the our our as a supply XXXX. Anicetti recently we logistics.
any We terms have will questions he Vince supply realigned might chain happy the product. in the today accordingly. be have internal and you our us with of Q&A, is organization of during answer to
ensure, standard in Near-term and product preapproval the both continuously I’ll respect with our strong center. place like we drug have in Now our and we meet FDA passed substance have to our inspection first by higher CMOs note drug and to processes facilities, to that we performance our Longer-term, somewhere with a experience support plan is consistent the this are according regulatory over years, to plus vigorous few aftermarket buildup and we to approval. grow preparing to it first geo about going launch believe trajectory. new of in may XX% to inventory after EMA
We that demand of have the if on to are biosimilar the we market. us plans level only enable even to place meet in
our commercial plan, continue of progress segment terms needs significant large the and the make in market segmenting terms of In we to each and clinic, hospital understanding small. of and
the the Our place leadership commercial and on track. support in infrastructure in our sales is is of buildout rest office back of
the meeting our the Health and Denver advancing for education as enthusiasm outreach in well where Most Hospital Hematology/Oncology been there at attending was Connect Pharmacy have Association events. efforts industry palpable in a We biosimilar. Atlanta, recently as Pharmacy Conference
a meetings, after and we and the issues thought insights a leaders, on important gaining prescribers interact number key with to addressed before launch. chance had these During of pharmacists, the
also market payers team regional the reimbursement to as for Medicare as and a senior launch. We national with access engage establishing well of have at objective commercial parity
strategies, out company the as discount market prices our completed not would provided Lastly, the landscape point of as competitive I analysis have unexpected we remains that has on not and time, unclear. yet this guidance
address with However, of may and we Senior calls. during to will happy be questions Jim Marketing us Hassard, President answer happy will today be our have Market Jim any issues and to future in of course, you Vice Q&A. those Access is
Having Coherus the to April the the successfully pursuant dance on Delaware March issued the XX, of Let so-called a patent. Court patent patent the judgment, CHS-XXXX. to legal We Judges District a the under issues this recommendation against up the Magistrate believe XXXX. claims concludes for final dismissing XXX Amgen’s me process it make brief dismissal all on XX, remark, with
we previously novel to thereby enabling for PPAR-Gamma CHS-XXX, inhibitor Let that, our make have announced pipeline. studies. extended work Phase X With me oral some remarks metabolite respect that completed the about we
neurologic indications such currently We which not MS, also indications options, NASH. selection evaluating indication include only are as metabolic as but such
estate awaiting no here at biosimilar, to guidance pursuant later of disclosed, was Amgen rest have litigation as Counsel, this outcome General pipeline, is our of answer respect are CHS-XXX updating we our Hooper our the With to time Sandoz, to you IPR CHS-XXXX, the but and Enbrel Brockhaus year. our in now the addition, declined, In this look on the respect to any the change forward we With on this your previously patent call. and we continued during IP Matt next build to to company’s questions that. of the we have on
Now before we go our Viret, have Chief Q&A, to the Jean let Officer, Financial financials. me review
